Preclinical work supports the potential of sotatercept to be a first-in-class disease-modifying therapy for pulmonary arterial hypertension (PAH) and to moving…
Articles by Patricia Inácio, PhD
A compound that scientists have been examining as a cancer therapy reduced blood pressure in pulmonary hypertension patients’ lungs, according…
Professor David Kiely, MD, and his team at Sheffield Teaching Hospitals NHS Foundation Trust in the United Kingdom, received…
Beta blockers, the cornerstone therapy for left-side heart failure, can improve pulmonary arterial hypertension, a small study indicates. The results…
African-Americans with pulmonary hypertension and without health insurance have a two-fold increased risk of dying of this disease compared to…
Adcirca (tadalafil) exerts a variety of positive effects that may explain why the therapy improves idiopathic pulmonary arterial hypertension…
Bellerophon Therapeutics has updated clinical trials testing its investigative INOpulse system for several forms of pulmonary hypertension (PH). The update is…
The Phase 4 multicenter, observational PaTTerN registry evaluating the use of Inomax (nitric oxide) in newborns with pulmonary hypertension (PH) has enrolled its first…
Adcirca (tadalafil) showed an acceptable safety profile and effectiveness in a real-world clinical cohort…
Pulmonary hypertension patients who receive prostacyclin for a long time are at higher risk of developing cardiovascular complications after a lung…
The average systemic sclerosis (SSc) patient burdened with pulmonary arterial hypertension (PAH) lives only four years after diagnosis, finds an…
Pulmonary arterial hypertension (PAH) patients who fail to respond completely to Adcirca (tadalafil) or Viagra (sildenafil) benefit from Letairis (ambrisentan)…